Intersect Capital’s DexCom DXCM Stock Holding History

Intersect Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,000	Closed	-$3.59M	–	378
2021 Q1	$3.59M	Buy	+40,000	New	+$3.75M	0.73%	26

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Intersect Capital's DXCM Position: Q2 2021 in Review

Intersect Capital sold out of DexCom (DXCM) in Q2 2021, closing a stake of 420 shares — an estimated $38K sold.

Intersect Capital first reported a position in DXCM in Q1 2021 and held it in 1 quarter. The position peaked at $38K in Q1 2021. 726 funds tracked by Wall St. Rank hold DXCM as of Q2 2021.

Intersect Capital reported no remaining DexCom position as of Q2 2021 after selling out during the quarter.
Intersect Capital sold 420 DexCom shares in Q2 2021, an estimated $38K.
Intersect Capital first reported a position in DexCom in Q1 2021 and held it in 1 quarter.
Intersect Capital's DexCom position peaked at $38K in Q1 2021.
726 funds tracked by Wall St. Rank held DexCom as of Q2 2021.

Based on Intersect Capital's 13F filing for Q2 2021, filed 10 Aug 2021.